Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : PFE save search
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.11%
H: 0.44%
C: -1.88%
abrysvo positive rsv
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Published: 2023-09-07 (Crawled : 05:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.55%
candidate disease report vaccine positive valneva results phase 2
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Published: 2023-05-30 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: -0.94%
positive trial results
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
Published: 2023-05-02 (Crawled : 12:20) - mindmed.co
MNMD | $8.7 -2.36% -2.41% 1.5M
|
n/a
|
| O: -1.04%
H: 0.79%
C: -1.06%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.2%
H: 2.1%
C: -0.59%
ALC | $79.55 1.38% -0.25% 1.1M
|
Health Technology
|
| O: -0.69%
H: 0.77%
C: 0.11%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.28%
H: 0.32%
C: 0.11%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.5%
H: 0.74%
C: -2.58%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -9.64%
H: 5.99%
C: 2.76%
FBRX 4 | $0.78 5.13% 8.3K
|
Health Technology
|
| O: -1.85%
H: 4.72%
C: 0.94%
momentum positive
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.69%
H: 0.52%
C: 0.17%
fda candidate vaccine rsv approval potential positive
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
Published: 2023-02-23 (Crawled : 09:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 1.09%
C: 0.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.55%
C: 0.01%
treatment biktarvy positive
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.39%
H: 0.07%
C: -0.46%
talzenna positive study
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
Published: 2022-11-10 (Crawled : 15:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.15%
H: 4.22%
C: 4.22%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.72%
H: 0.47%
C: -0.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -4.59%
H: 3.28%
C: 3.06%
covid-19 chmp children vaccine positive
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
Published: 2022-11-02 (Crawled : 00:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.5%
H: 0.84%
C: -1.47%
tg4001 trial positive results
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 3.11%
H: 0.88%
C: 0.02%
candidate global vaccine respiratory virus trial positive
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
Published: 2022-10-25 (Crawled : 15:20) - biospace.com/
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.27%
H: 0.0%
C: -2.17%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.59%
H: 1.21%
C: 0.71%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.57%
H: 1.16%
C: 0.94%
offering treatment antibody hiv potential positive
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
Published: 2022-10-19 (Crawled : 16:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.41%
H: 0.36%
C: -1.82%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.37%
H: 0.37%
C: -6.97%
comirnaty comirnaty® chmp children positive
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Published: 2022-10-13 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -4.1%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.78%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.64%
H: 3.35%
C: 2.92%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.67%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -2.2%
H: 6.32%
C: 4.76%
trial positive
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
Published: 2022-10-04 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.25%
H: 1.33%
C: 0.47%
topline trial positive results
Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Published: 2022-09-16 (Crawled : 12:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.33%
H: 1.15%
C: -0.13%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.82%
H: 3.27%
C: 3.0%
comirnaty comirnaty® chmp authorization positive
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
Published: 2022-09-15 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.09%
H: 0.39%
C: -0.37%
candidate vaccine trial positive results
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
Published: 2022-09-01 (Crawled : 14:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.51%
H: 1.07%
C: 1.07%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.2%
H: 3.35%
C: 3.3%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -3.04%
H: 0.45%
C: 0.05%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.68%
H: 1.61%
C: 1.5%
covid-19 chmp vaccine positive
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.